TOPLINE: High-dose ergocalciferol (a vitamin D analog) can prolong the remission period of type 1 diabetes (T1D) by preserving the function of insulin-producing beta cells in […]

TOPLINE: Changes in plasma growth hormone mediators such as growth hormone receptor (GHR) and insulin-like growth factor-binding protein 1 (IGFBP-1) were associated with glycemic failure in […]

TOPLINE: Patients on weekly glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have high residual gastric content, a major risk factor for aspiration under anesthesia, despite following fasting […]

A new cohort study has found an increased risk for stillbirth among women with obesity, particularly at term.  The study analyzed data from > 680,000 births […]

The odds of having obesity in middle age are sixfold higher if both parents also had obesity in middle age, showed data that shed some light […]

A new position statement from the International Diabetes Federation advises using a 1-hour 75-g oral glucose tolerance test (OGTT) to improve identification of people at risk […]

TOPLINE: Higher weekly levels of moderate physical activity are associated with a lower risk for chronic kidney disease (CKD) in patients with type 2 diabetes (T2D) […]

The US Food and Drug Administration (FDA) has approved the anti-obesity drug semaglutide 2.4 mg injection (Wegovy) for reducing cardiovascular risk in adults with overweight or […]

COPENHAGEN (Reuters) – Novo Nordisk’s CEO on Friday said compounded semaglutide in the United States is a serious health issue. Demand for Novo’s wildly popular weight-loss […]